Mega Genomics Limited disclosed that it repurchased 82,600 ordinary shares on 14 September 2026 via on-exchange transactions, paying between HKD 7.15 and HKD 7.165 per share. The outlay totalled HKD 0.59 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.04% to 223.25 million shares from 223.34 million shares. The repurchased stock has been retained as treasury shares, lifting the treasury share balance to 1.05 million. Total issued shares remain unchanged at 224.30 million.

Since receiving shareholder approval for a 10% buy-back mandate on 21 May 2026—covering up to 22.43 million shares—Mega Genomics has repurchased 1.05 million shares, representing 0.47% of the company’s issued share base on the mandate date. Under Hong Kong listing rules, the company is subject to a 30-day moratorium on new share issues or treasury share disposals, effective until 14 October 2026.

The board confirmed that the repurchase complied with all applicable Main Board listing rules and regulatory requirements, and all related payments have been settled.